NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Soligenix's RiVax(R) Vaccine and Biodefense Preparedness
TL;DR
Soligenix's RiVax vaccine offers a strategic advantage in biodefense with its thermostability enabling stockpiling for rapid deployment during ricin threats.
RiVax works by providing protective efficacy against ricin toxin through a heat-stabilized vaccine platform, supported by animal model studies and government funding.
This vaccine development enhances global health security by protecting vulnerable populations and first responders from accessible biological threats like ricin.
Ricin can be made from castor beans using common tools, highlighting the need for countermeasures like Soligenix's durable vaccine candidate.
Found this article helpful?
Share it with your network and spread the knowledge!
The article discusses Soligenix Inc.'s development of RiVax(R), a vaccine candidate to protect against ricin exposure, and how this positions the company in biodefense preparedness efforts.
Ricin is a lethal toxin that can be easily produced from castor beans using common tools, making it an accessible biological threat that requires effective countermeasures for public health security.
RiVax(R) demonstrates durability through thermostability and strong protective efficacy in animal models, which could allow for strategic stockpiling in national stockpiles and rapid deployment during ricin incidents.
First responders, military personnel, and vulnerable civilian populations would benefit from rapid deployment of the vaccine should a ricin incident occur.
Soligenix has a Specialized BioTherapeutics business segment developing treatments for rare diseases like cutaneous T-cell lymphoma, psoriasis, and inflammatory diseases, and a Public Health Solutions segment that includes RiVax(R) and other vaccine programs.
The company's vaccine programs have received support from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
Soligenix incorporates its proprietary heat stabilization platform technology called ThermoVax(R) in the development of its vaccine programs.
Readers can visit the company's website at www.Soligenix.com or access the latest news and updates at https://ibn.fm/SNGX.
A recent counter-terrorism operation in India where authorities foiled a ricin plot underscored how easily accessible castor beans can be transformed into the deadly toxin.
The continued development and regulatory progression of RiVax(R) may inform broader strategies for biodefense and emergency readiness against accessible biological threats that challenge health security systems.
Curated from InvestorBrandNetwork (IBN)
